+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Recent advances in the development of catalytic inhibitors of human DNA topoisomerase IIα as novel anticancer agents



Recent advances in the development of catalytic inhibitors of human DNA topoisomerase IIα as novel anticancer agents



Current Medicinal Chemistry 20(5): 694-709



DNA topoisomerases comprise an important family of enzymes that catalyse the induction of topological changes (e.g. relaxation/ supercoiling, catenation/decatenation and knotting/unknotting) in the DNA molecule. These enzymes perform their functions by creating transient either single-stranded or double-stranded breaks in the DNA molecule. Due to their ability to modulate the topology of the DNA molecule, DNA topoisomerases play vital roles in replication, transcription, chromosome separation and segregation, and thus represent an important collection of design targets for novel anticancer drugs. The aim of this review is to provide an overview of the development of catalytic inhibitors of the human topoisomerase IIα enzyme--an important member of the DNA topoisomerase family--as potential novel anticancer agents. The group of catalytic topoII inhibitors is classified into four types according to their molecular mechanism of action: inhibitors that bind to the ATP binding site, inhibitors that prevent the ATP hydrolysis step and trap the enzyme in a closed clamp, inhibitors that block the DNA cleavage and inhibitors that prevent the enzyme binding to the DNA. One of the important considerations highlighted throughout this review is the structure-based perspective of inhibitor design, giving the reader a medicinal chemist's perspective on this vibrant and active field of drug design research.

(PDF emailed within 1 workday: $29.90)

Accession: 055398861

Download citation: RISBibTeXText

PMID: 23210851


Related references

Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs. Current Medicinal Chemistry 17(35): 4270-4290, 2011

Recent developments of DNA poisons--human DNA topoisomerase IIα inhibitors--as anticancer agents. 2013

Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents. Medicinal Research Reviews 17(4): 367-425, 1997

Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents. Current Drug Targets 13(11): 1432-1444, 2013

Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia 17(8): 1470-1481, 2003

Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents. Mini Reviews in Medicinal Chemistry 16(15): 1219-1229, 2016

Recent Advances in the Design and Synthesis of c-Met Inhibitors as Anticancer Agents (2014-Present). Current Medicinal Chemistry 24(1): 57-64, 2016

Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents. Journal of Medicinal Chemistry 45(3): 721-739, 2002

Recent Advances in Development of Polyphenols as Anticancer Agents. Mini Reviews in Medicinal Chemistry 18(15): 1265-1269, 2018

Recent Advances in the Development of Indazole-based Anticancer Agents. Chemmedchem 13(15): 1490-1507, 2018

The Recent Development of Farnesyltransferase Inhibitors as Anticancer and Antimalarial Agents. Mini Reviews in Medicinal Chemistry 15(10): 837-857, 2016

Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs. European Journal of Medicinal Chemistry 108: 495-504, 2016

Recent advances in the development of 1,8-naphthalimide based DNA targeting binders, anticancer and fluorescent cellular imaging agents. Chemical Society Reviews 42(4): 1601-1618, 2013

Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents. Chemistry and Biology 21(11): 1433-1443, 2015

Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents. Oncotarget 8(4): 7181-7200, 2016